Heart rate on the monitor of an electrocardiogram. MUTLU KURTBAS ISTOCK GETTY IMAGES
Success with MedTech start-ups in Silicon Valley
The foundation of our strategy is our partnership with Shifamed, the medical technology innovation hub located in the heart of the Silicon Valley and building the next generation medical products that improve clinical standards and impact patients’ lives. We have access and will primarily invest in Shifamed portfolio companies benefitting from their track-record of six exits out of six ventures.
We launched our first Fund in November 2021 and completed a final close in November 2022 totalling $40.6M. The Fund I is now fully deployed and therefore, we are currently in the process of working on Fund II.
De-risking venture strategy
With the MedTech Venure Capital Fund II, Picard Angst is pursuing a strategy that attempts to combine the enormous value creation potential of private equity venture capital with a significantly reduced risk profile. It focuses primarily on the following three factors.
Fast Follower
Learn more
Growth Strategy
Learn more
Due Dilligence
Learn more
The PA MedTech VC Fund
Product information
The Picard Angst MedTech Venture Capital Fund is a risk capital fund that makes direct investment in the most promising MedTech start-ups in Silicon Valley. Thanks to its consistent fast follower strategy, it offers high potential returns and minimised risk, compared to traditional VC investments.
MedTech Venture Capital Fund II
| Key data | |
| Investors | Professional / Institutional Investors (Well-Informed Investors) |
| Fund volume | USD 50 to 100 million |
| Minimum investment | USD 150’000 |
| Investment criteria | Big Medical Market / Fast Follower Opportunity |
| Sectors | Cardiology, Ophthalmology, Digital Health, AI, Robotics |
| Stage | Early stage, pre-revenue |
| Fund Life | 5 years + 1 + 1 |
| Exit strategy | After around 3-5 years |
| Returns | 3 to 5 times |
| Fund launch date | May 2024 |
| ISIN | LU2792002177 (Class G), LU2792002334 (Class H), LU2792002508 (Class I) |
| Marketing authorisation | Authorized for institutional investors in Luxemburg, Switzerland and EU (Specific jurisdictions to be approved on demand) |
| Costs | |
| Management fee (p.a.) | 2% |
| Performance fee | 20% |
| Organisation | |
| Investment manager | Picard Angst Ltd. |
| Management company | NSPartners (Lux) |
| Custodian bank | UBS (Lux) |
| Legal structure | Reserved Alternative Investment Fund (RAIF) |
Your benefits
Fast exits
On average <5 years until exit
Return
Average 4.7x investment
Lower risk
Compared to venture investments
Portfolio
The PA MedTech VC Fund invests in Fast-Follower start-ups developing next generation medical products in cardio-vascular, ophthalmology, using digital health and AI technology, areas that are growing rapidly due to structural factors. Here are some examples of investments we have made:
"Generate sustainable impact for patients and your portfolio."
Peter Pilavachi, General Partner and Portfolio Manager
25 years, 6 exits, 200 patents
The Picard Angst MedTech VC Fund is providing access to the Shifamed MedTech innovation hub, based in Silicon Valley. The successful medical technology entrepreneur Amr Salahieh launched the campus in 2009 and the start-ups benefit from state-of-the-art research laboratories, clean rooms and production facilities. But they also benefit from the expertise of the management team, which has 25 years of experience in clinics, technology, production and marketing. The track record: 6 exits and over 200 patents.
Your contact
Peter Pilavachi
General Partner & Portfoliomanager «PA MedTech VC Fund»
+
Important legal information:
We would like to inform you that telephone calls made to our phone lines are recorded. We assume that you are in agreement with this when you call.
This presentation draft represents a future project from Picard Angst. It is not an offer or invitation to buy or sell securities. It is intended for informational use only. Investments should only be made after the fund documentation in question has been read thoroughly. This presentation does not contain binding information; the offer documentation is the sole legally binding documentation.
The “Directives on the Independence of Financial Research” from the Swiss Bankers Association do not apply to this presentation. We wish to make you aware that it cannot be excluded that Picard Angst AG has a vested interest in the development of the price of individual titles or all the titles listed in this document.
The value and returns of the shares can increase or decrease. They are influenced by market volatility and currency fluctuation. Picard Angst AG accepts no liability for any losses. Past performance of values and returns is no indicator of ongoing and future performance. The performance of values and returns does not take into account any charges and fees incurred upon purchase, redemption and/or exchange of the shares. The allocation by country, currency and individual items, and any benchmarks stated, can change at any time within the framework of the investment policies stated in the legal prospectus.
All statements can be changed without prior notice. Statements can differ from estimates given in other documents published by Picard Angst AG, including research publications. Neither the entire document nor parts thereof may be reused or redistributed. While Picard Angst AG is of the opinion that the information included herein draws on reliable sources, Picard Angst cannot guarantee the quality, accuracy, validity or completeness of the information contained within this document.
If the fund, partial fund or share class is not registered for public offer and sale, the sale of shares can only be undertaken within the framework of private placements, or in the institutional domain, with regard to applicable local laws. The fund may not be sold in the USA nor to US citizens, neither directly nor indirectly.
Picard Angst AG is an asset manager handling collective capital investments pursuant to the Federal Law on Collective Capital Investments and is subject to the oversight of the Swiss Financial Market Supervisory Authority.